Yıl: 2018 Cilt: 27 Sayı: 2 Sayfa Aralığı: 182 - 186 Metin Dili: İngilizce İndeks Tarihi: 09-05-2019

Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report

Öz:
VR is a rare condition that causes a sudden vision loss. Although VR is considered to be rare but a serious complication of surgery. Ourcase was a 64 years old woman was presented with preretinal haemorrhage including macular area in right eye secondary to VR afteran uneventful cataract surgery under general anesthesia. Her vision was counting fi ngers after the surgery. Although surgical correctionor Nd:YAG laser hyaloidotomy was available she was treated with single intravitreal TPA, intravitreal bevacizumab and 0.2cc SF6 gaseinjection. There was signifi cant reduction of premacular haemorrhage and her vision improved to 7/10 after injection on the fi nal visit.
Anahtar Kelime:

Konular: Göz Hastalıkları

Mezenterik Fibromatozise Bağlı Malign Hipertansiyon: Olgu Sunumu

Öz:
Valsalva retinopatisi (VR) ani görme kaybına neden olabilen nadir bir durumdur. VR nadir görülmekle birlikte önemli bir cerrahi komplikasyondur. 64 yaşında bayan hastada komplikasyonsuz katarakt cerrahisi sonrası VR’ne bağlı makuler alanı içine alan preretinal kanama saptanmıştır. Cerrahi sonrası hastanın görme seviyesi el hareketi düzeyindedir. Cerrahi tedavi veya Nd:YAG lazer hyaloidotomi mümkün olsa da hastamız intravitreal TPA, intravitreal bevacizumab ve 0.2cc SF6 gaz injeksiyonu ile tedavi edilmiştir.Son muayenede premakuler kanamada gerileme saptanmış ve hastanın görmesi 7/10 düzeyine yükselmiştir.
Anahtar Kelime:

Konular: Göz Hastalıkları
Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Bibliyografik
  • Keith NM, Wagener HP, Kernohan JW. The syndrome of malignant hypertension. Arch Intern Med. 1928; 41: 141-88.
  • Richard JG. Current therapy in nephrology and hyper- tension. The CV Mosby Company. 1984-1985; 324-33.
  • Mitchell RN, Schoen FJ. Blood vessels. In. Kumar, Ab- bas & Fausto, et al. Robbins and Cotran Pathologic Basis of Disease. Philadelphia, Pennsylvania, USA: Saunders Elsevier, 2010; 487–528.
  • Bar-Maor JA, Shabshin U. Mesenteric fi bromatosis. J Pediatr Surg. 1993; 28: 1618-9.
  • Nuyttens JJ, Rust PF, Thomas CR Jr., Turrisi AT. Sur- gery versus radiation therapy for patients with aggres- sive fi bromatosis or desmoid tumors. Cancer. 2000; 88: 1517-23.
  • Smith AJ, Lewis JJ, Merchant NB, et al. Surgical mana- gement of intraabdominal desmoid tumors. Br J Surg. 2000; 87: 608-13.
  • Kreuzberg B, Koudelova J, Ferda J, et al. Diagnostic problems of abdominal desmoid tumors in various loca- tions. European Journal of Radiology. 2007; 62: 180-5.
  • Vandevenne JE, De Schepper AM, De Beuckeleer L, et al. New concepts in understanding evolution of desmoid tumors: MR imaging of 30 lesions. Eur Radiol. 1997; 7: 1013–9.
  • Murphy HP, Chew EY. Hypertension: In: Ryan SJ, Sc- hachat AP, Murphy RP, Pätz A, ed. Retina. St Louis: The Mosby Company. 1989: 2: 449-55.
  • Walsh JBM. Hypertensive retinopathy. Descriptions, classifi cation and prognosis. Ophthalmology. 1992: 89: 1127-31.
  • Jampol LM. Ocular manifestations of selected systemic disease. In: Peyman AG, Sanders DR, Goldberg MF, ed. Principles and practice of ophthalmology. Philadelphia: WB Saunders Company. 1980: 3: 1633-40.
  • Sutton RJ, Thomas JM. Desmoid tumours of the anterior abdominal wall. European Journal of Surgical Oncology. 1999; 25: 398-400.
  • Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. Incidence, sex- , age. and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982; 77: 665-73.
  • Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinico- pathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999; 23: 1109-18.
  • Chanco G, Rose EF. Mesenteric fi bromatosis following colectomy for familial polyposis. Arch Surg. 1972; 104: 851-2.
APA Mirza E, ÖZKAĞNICI A, Zengin N, okka m, MİRZA D (2018). Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. , 182 - 186.
Chicago Mirza Enver,ÖZKAĞNICI Ahmet,Zengin Nazmi,okka mehmet,MİRZA Deniz Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. (2018): 182 - 186.
MLA Mirza Enver,ÖZKAĞNICI Ahmet,Zengin Nazmi,okka mehmet,MİRZA Deniz Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. , 2018, ss.182 - 186.
AMA Mirza E,ÖZKAĞNICI A,Zengin N,okka m,MİRZA D Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. . 2018; 182 - 186.
Vancouver Mirza E,ÖZKAĞNICI A,Zengin N,okka m,MİRZA D Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. . 2018; 182 - 186.
IEEE Mirza E,ÖZKAĞNICI A,Zengin N,okka m,MİRZA D "Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report." , ss.182 - 186, 2018.
ISNAD Mirza, Enver vd. "Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report". (2018), 182-186.
APA Mirza E, ÖZKAĞNICI A, Zengin N, okka m, MİRZA D (2018). Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. Retina-Vitreus, 27(2), 182 - 186.
Chicago Mirza Enver,ÖZKAĞNICI Ahmet,Zengin Nazmi,okka mehmet,MİRZA Deniz Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. Retina-Vitreus 27, no.2 (2018): 182 - 186.
MLA Mirza Enver,ÖZKAĞNICI Ahmet,Zengin Nazmi,okka mehmet,MİRZA Deniz Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. Retina-Vitreus, vol.27, no.2, 2018, ss.182 - 186.
AMA Mirza E,ÖZKAĞNICI A,Zengin N,okka m,MİRZA D Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. Retina-Vitreus. 2018; 27(2): 182 - 186.
Vancouver Mirza E,ÖZKAĞNICI A,Zengin N,okka m,MİRZA D Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report. Retina-Vitreus. 2018; 27(2): 182 - 186.
IEEE Mirza E,ÖZKAĞNICI A,Zengin N,okka m,MİRZA D "Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report." Retina-Vitreus, 27, ss.182 - 186, 2018.
ISNAD Mirza, Enver vd. "Mesenteric Fibromatosis Due to Malignant Hypertension: A Case Report". Retina-Vitreus 27/2 (2018), 182-186.